New Dengue Vaccine Deal
Dr. Reddy's and Takeda Sign Exclusive Agreement to Distribute Qdenga Vaccine in India
Anonymous
Key Points
1
The World Health Organization recorded 14.4 million dengue cases and 11,201 deaths globally in 2024; India accounted for 232,425 cases and 233 deaths that year.
2
Takeda expects initial demand to be stronger among children, with adult vaccination likely to grow as public awareness and adoption increase.
3
Takeda said its broader manufacturing strategy is aimed at reaching global production capacity of 100 million QDENGA doses per year by 2030.
4
The companies’ pricing study was designed to support broad and sustainable access, with Takeda saying the Indian price would be based on local affordability rather than benchmarked against another country.
5
Dr. Reddy’s shares rose by more than 2% on September 18, making the company one of the day’s top Nifty gainers after the distribution agreement was announced.
Dr. Reddy's Laboratories has signed an exclusive deal with Takeda Pharmaceutical to distribute QDENGA, India's first dengue vaccine, in the private market starting in the first half of 2027 Economic Times. The two-dose vaccine protects against all four dengue virus serotypes and is approved for people aged 4 to 60 Tribune India. Initial doses will come from Takeda's German facility, which can produce about 50 million doses annually, with plans to eventually expand capacity through a partnership with Biological E Economic Times.
India recorded 232,425 dengue cases and 233 deaths in 2024, part of a global burden of 14.4 million cases and 11,201 deaths Economic Times. QDENGA requires two doses given three months apart and needs no prior-infection screening. The companies are designing pricing to support broad access based on local affordability Economic Times.
How the Partnership Divides Responsibility
Takeda retains control over the vaccine's legal, medical, and brand strategy, plus manufacturing and all public-sector sales rights Media Brief. Dr. Reddy's handles promotion and distribution in India's private paediatric and adult markets. Both companies may eventually seek inclusion in India's universal immunisation programme, which would dramatically expand the vaccine's reach Economic Times.
A Two-Pronged Strategy for Production Scaling
Takeda's German facility can currently produce about 50 million doses annually Economic Times. The planned partnership with Biological E is expected to add another 50 million doses, primarily for large-scale public programmes. By 2030, Takeda aims to reach global production capacity of 100 million QDENGA doses per year Economic Times.
Strong Initial Demand Among Children Expected
Takeda anticipates stronger early uptake among children, with adult vaccination likely to grow as public awareness and adoption increase Economic Times. The company's pricing study was designed to support sustainable access, with the Indian price based on local affordability rather than copied from other countries. Dr. Reddy's shares rose more than 2% on September 18 after the agreement was announced, making it one of the day's top Nifty gainers Economic Times.
Sentiment
Mostly PositiveNEGATIVENEUTRALPOSITIVE
Publishers
24
Articles
24
Reach
48
A
AnonymousAuthor
